AbbVie is terminating its long‑running R&D partnership with Alphabet’s Calico Labs after 11 years, internal documents and reporting show, and plans workforce reductions tied to the wind‑down. The multi‑hundred‑million‑dollar collaboration focused on aging and age‑related diseases, producing several early‑stage programs including fosigotifator; clinical failures in neurodegeneration contributed to the reassessment. AbbVie’s shift away from small‑molecule discovery toward injectables and genetic medicines was cited as a strategic driver. The split will realign assets and priorities at both companies and raises questions about the fate of shared preclinical programs and the redeployment of talent and platforms built under the collaboration.